Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage

Objective To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). Methods We performed an observational study of 80 patients with SLE included in a previous cross‐sectional study of 25(OH)...

Full description

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 62; no. 8; pp. 1160 - 1165
Main Authors Ruiz‐Irastorza, Guillermo, Gordo, Susana, Olivares, Nerea, Egurbide, Maria‐Victoria, Aguirre, Ciriaco
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.08.2010
Subjects
Online AccessGet full text
ISSN2151-464X
2151-4658
2151-4658
DOI10.1002/acr.20186

Cover

Abstract Objective To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). Methods We performed an observational study of 80 patients with SLE included in a previous cross‐sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D3 was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0–10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed. Results Sixty patients took vitamin D3. Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty‐seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively). Conclusion Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D3 replacement.
AbstractList To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). We performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D(3) was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0-10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed. Sixty patients took vitamin D(3). Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively). Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D(3) replacement.
Objective To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE). Methods We performed an observational study of 80 patients with SLE included in a previous cross‐sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D3 was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0–10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed. Results Sixty patients took vitamin D3. Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty‐seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively). Conclusion Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D3 replacement.
To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE).OBJECTIVETo analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE).We performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D(3) was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0-10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed.METHODSWe performed an observational study of 80 patients with SLE included in a previous cross-sectional study of 25(OH)D, reassessed 2 years later. Oral vitamin D(3) was recommended in those with low baseline 25(OH)D levels. The relationship between changes in 25(OH)D levels from baseline and changes in fatigue (measured by a 0-10 visual analog scale [VAS]), SLE activity (measured by the Systemic Lupus Erythematosus Disease Activity Index [SLEDAI]), and irreversible organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]) were analyzed.Sixty patients took vitamin D(3). Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively).RESULTSSixty patients took vitamin D(3). Mean 25(OH)D levels increased among all treated patients (P = 0.044), in those with baseline vitamin D levels <30 ng/ml (P < 0.001), and in those with baseline vitamin D levels <10 ng/ml (P = 0.005). Fifty-seven patients (71%) still had 25(OH)D levels <30 ng/ml and 5 (6%) had 25(OH)D levels <10 ng/ml. Inverse significant correlations between 25(OH)D levels and the VAS (P = 0.001) and between changes in 25(OH)D levels and changes in the VAS in patients with baseline 25(OH)D levels <30 ng/ml (P = 0.017) were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25(OH)D levels (P = 0.87 and P = 0.63, respectively).Increasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D(3) replacement.CONCLUSIONIncreasing 25(OH)D levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25(OH)D levels on SLE severity, although they are limited by the insufficient 25(OH)D response to the recommended regimen of oral vitamin D(3) replacement.
Author Gordo, Susana
Olivares, Nerea
Aguirre, Ciriaco
Ruiz‐Irastorza, Guillermo
Egurbide, Maria‐Victoria
Author_xml – sequence: 1
  givenname: Guillermo
  surname: Ruiz‐Irastorza
  fullname: Ruiz‐Irastorza, Guillermo
  email: r.irastorza@euskalnet.net
– sequence: 2
  givenname: Susana
  surname: Gordo
  fullname: Gordo, Susana
– sequence: 3
  givenname: Nerea
  surname: Olivares
  fullname: Olivares, Nerea
– sequence: 4
  givenname: Maria‐Victoria
  surname: Egurbide
  fullname: Egurbide, Maria‐Victoria
– sequence: 5
  givenname: Ciriaco
  surname: Aguirre
  fullname: Aguirre, Ciriaco
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20235208$$D View this record in MEDLINE/PubMed
BookMark eNp1kU9P3DAQxS0EKpRy4AtUvlVILDh21nF6Qwv9IyEhISr1Zjn2eNdV4iwZBxTx5WvYpYcK5jKj0e-9w3sfyW7sIxByXLCzgjF-buxwxlmh5A454MW8mJVyrnb_3eXvfXKE-IflEVwpUX8g-5xxMedMHZCnxcrEJSANkT6EZLq8L2kLD9C-_NYmBYgJ6WNIK4oTJuiCpe24HpHCMKUVdCb1OOJXeuU92Iz2kfosW45wSl1AMAjU2BSy_3RKTXTUmc4s4RPZ86ZFONruQ_Lr29Xd4sfs-ub7z8XF9cwKXspZVUrRNI2vgDXSWyZdUXnpgBlRg3eqqq2QTdlYI6VvLHDvTaFqLrxw9bx04pB82fiuh_5-BEy6C2ihbU2EfkRdlaoumapFJj9vybHpwOn1EDozTPo1rwycbwA79IgDeG1zaCn0MQ0mtLpg-rkUnUvRL6Vkxcl_ilfTt9it-2NoYXof1BeL243iL1-DnUE
CitedBy_id crossref_primary_10_1136_ard_2010_148494
crossref_primary_10_1371_journal_pgph_0002475
crossref_primary_10_1016_j_rbre_2017_08_001
crossref_primary_10_3899_jrheum_111594
crossref_primary_10_1016_j_lpm_2014_03_009
crossref_primary_10_1186_s13293_021_00358_3
crossref_primary_10_2174_1874312901812010226
crossref_primary_10_1177_0961203314559089
crossref_primary_10_1155_2017_7687053
crossref_primary_10_1016_j_medcle_2017_12_040
crossref_primary_10_1002_acr_20568
crossref_primary_10_1038_nrrheum_2013_71
crossref_primary_10_1177_0961203317706557
crossref_primary_10_1002_acr_22621
crossref_primary_10_1016_j_autrev_2012_07_007
crossref_primary_10_1016_j_reuma_2024_07_004
crossref_primary_10_1016_j_autrev_2017_09_011
crossref_primary_10_1371_journal_pone_0270569
crossref_primary_10_1097_BOR_0b013e32835cfc16
crossref_primary_10_4137_IMI_S40035
crossref_primary_10_1111_1756_185X_12489
crossref_primary_10_1016_j_reumae_2024_10_003
crossref_primary_10_1016_j_revmed_2011_11_010
crossref_primary_10_1016_j_bcp_2024_116417
crossref_primary_10_1093_rheumatology_kew212
crossref_primary_10_1136_annrheumdis_2016_209157
crossref_primary_10_4161_derm_20443
crossref_primary_10_1016_j_semarthrit_2010_07_009
crossref_primary_10_1002_acr_21840
crossref_primary_10_1017_S0029665111001613
crossref_primary_10_1051_mbcb_2020062
crossref_primary_10_4103_jioh_jioh_61_22
crossref_primary_10_1007_s00011_020_01337_x
crossref_primary_10_1007_s10067_014_2530_5
crossref_primary_10_1002_acr_21839
crossref_primary_10_1007_s12016_013_8361_3
crossref_primary_10_3109_03009742_2012_697189
crossref_primary_10_1007_s10067_012_2021_5
crossref_primary_10_3390_nu12030789
crossref_primary_10_1016_j_rbr_2017_05_009
crossref_primary_10_1080_17482631_2019_1632111
crossref_primary_10_1016_j_autrev_2018_01_004
crossref_primary_10_1016_j_amjms_2019_04_020
crossref_primary_10_3390_ijms19082355
crossref_primary_10_1007_s00296_016_3497_0
crossref_primary_10_1136_jnnp_2014_308374
crossref_primary_10_1136_lupus_2014_000027
crossref_primary_10_1177_0961203311421798
crossref_primary_10_1177_1076029618786574
crossref_primary_10_3889_oamjms_2014_119
crossref_primary_10_3389_fimmu_2020_616483
crossref_primary_10_1038_s41584_023_00944_2
crossref_primary_10_1177_0961203318796293
crossref_primary_10_1007_s00198_017_4316_5
crossref_primary_10_1016_j_ejr_2011_07_004
crossref_primary_10_1016_j_lpm_2013_06_014
crossref_primary_10_1016_j_rbr_2014_09_008
crossref_primary_10_2217_ijr_12_78
crossref_primary_10_3389_fimmu_2023_1147447
crossref_primary_10_1016_j_ejr_2014_07_005
crossref_primary_10_1016_j_biopha_2020_110256
crossref_primary_10_1007_s11926_011_0188_4
crossref_primary_10_1186_ar3161
crossref_primary_10_3390_nu16020221
crossref_primary_10_1177_0961203311401457
crossref_primary_10_3389_fimmu_2015_00513
crossref_primary_10_3389_frph_2022_936810
crossref_primary_10_3892_etm_2018_6986
crossref_primary_10_1007_s13317_017_0101_x
crossref_primary_10_1177_0961203314540966
crossref_primary_10_46497_ArchRheumatol_2022_8996
crossref_primary_10_1016_j_medcli_2017_12_007
crossref_primary_10_2217_ijr_12_4
crossref_primary_10_1016_j_autrev_2016_03_015
crossref_primary_10_1016_j_ejr_2020_08_005
crossref_primary_10_1007_s12026_017_8903_5
crossref_primary_10_1093_rheumatology_key398
crossref_primary_10_1177_0961203311425530
crossref_primary_10_1016_j_jcm_2011_06_006
crossref_primary_10_1016_j_yexmp_2023_104866
crossref_primary_10_1016_j_autrev_2017_11_004
crossref_primary_10_1016_j_medcli_2016_01_013
crossref_primary_10_1016_j_medcle_2016_06_033
crossref_primary_10_7759_cureus_25896
crossref_primary_10_1371_journal_pone_0055275
crossref_primary_10_3390_jcm10173996
crossref_primary_10_2217_nmt_11_59
crossref_primary_10_1007_s00296_010_1736_3
crossref_primary_10_1177_0961203316635289
crossref_primary_10_1586_eci_13_19
crossref_primary_10_2174_1874312901812010201
crossref_primary_10_1038_nrdp_2016_39
crossref_primary_10_1007_s12070_021_02913_1
crossref_primary_10_1016_S0151_9638_13_70142_X
crossref_primary_10_1016_j_jaut_2016_06_010
crossref_primary_10_1016_j_rbre_2014_09_010
crossref_primary_10_1136_lupus_2020_000441
crossref_primary_10_1177_0961203314566636
crossref_primary_10_1186_s41927_021_00223_1
crossref_primary_10_3899_jrheum_180831
crossref_primary_10_1177_0961203314522338
crossref_primary_10_1002_art_37953
crossref_primary_10_3390_nu11102315
Cites_doi 10.1097/BOR.0b013e32830a991b
10.1056/NEJMra070553
10.1007/s11926-008-0044-3
10.1373/clinchem.2004.040683
10.1016/j.autrev.2005.05.009
10.1093/rheumatology/ken121
10.1002/art.24785
10.1196/annals.1398.061
10.4049/jimmunol.179.3.1634
10.1177/0961203307085879
10.1093/rheumatology/ken394
10.1196/annals.1351.031
10.1097/MAJ.0b013e318134eeb6
10.1093/ajcn/75.4.611
10.1196/annals.1398.044
10.1093/ajcn/80.6.1717S
10.1016/j.atherosclerosis.2008.10.033
10.1001/archinte.168.15.1629
10.1002/art.1780400928
10.1002/art.23113
10.1136/bmj.326.7399.1124
10.1007/BF02207671
ContentType Journal Article
Copyright Copyright © 2010 by the American College of Rheumatology
Copyright_xml – notice: Copyright © 2010 by the American College of Rheumatology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1002/acr.20186
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2151-4658
EndPage 1165
ExternalDocumentID 20235208
10_1002_acr_20186
ACR20186
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Actelion
– fundername: BIOEF
GroupedDBID .3N
.GA
.Y3
0R~
10A
1OC
24P
31~
33P
4.4
50Z
51W
51X
52N
52O
52P
52R
52S
52T
52W
52X
53G
5VS
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCUV
ABIJN
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADMGS
ADOZA
ADXAS
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BRXPI
BY8
D-6
D-7
D-E
D-F
DCZOG
DR2
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
GODZA
H.X
HF~
HGLYW
HZ~
J0M
J5H
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N04
N05
NF~
O66
O9-
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
QB0
ROL
SUPJJ
TEORI
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIK
WOHZO
WQJ
WVDHM
WXI
WXSBR
XG1
ZZTAW
~WT
AAYXX
ABJNI
AEYWJ
AGHNM
AGYGG
CITATION
OVD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3246-7463bbbf7e0b6fc06d17f6de0a39efd879c36b4bca66fbce2ffa18923f3d954d3
IEDL.DBID DR2
ISSN 2151-464X
2151-4658
IngestDate Fri Jul 11 11:59:24 EDT 2025
Mon Jul 21 06:01:45 EDT 2025
Tue Jul 01 01:37:17 EDT 2025
Thu Apr 24 22:54:55 EDT 2025
Wed Jan 22 16:26:40 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3246-7463bbbf7e0b6fc06d17f6de0a39efd879c36b4bca66fbce2ffa18923f3d954d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20235208
PQID 748940893
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_748940893
pubmed_primary_20235208
crossref_citationtrail_10_1002_acr_20186
crossref_primary_10_1002_acr_20186
wiley_primary_10_1002_acr_20186_ACR20186
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2010
2010-08-00
2010-Aug
20100801
PublicationDateYYYYMMDD 2010-08-01
PublicationDate_xml – month: 08
  year: 2010
  text: August 2010
PublicationDecade 2010
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
PublicationTitle Arthritis care & research (2010)
PublicationTitleAlternate Arthritis Care Res (Hoboken)
PublicationYear 2010
Publisher John Wiley & Sons, Inc
Publisher_xml – name: John Wiley & Sons, Inc
References 2007; 357
2007; 179
1997; 40
2004; 50
2000; 27
2003; 326
2002; 75
2006; 54
2009; 61
1995; 14
2008; 17
2008; 47
2007; 1109
2006; 5
2008; 10
2008; 335
2006; 1069
2001; 28
2008; 20
2008; 168
2004; 80
2007; 57
2009; 48
2009; 205
e_1_2_7_5_2
Martins DC (e_1_2_7_24_2) 2006; 54
e_1_2_7_4_2
Huisman AM (e_1_2_7_26_2) 2001; 28
e_1_2_7_3_2
e_1_2_7_2_2
Gladman DD (e_1_2_7_10_2) 2000; 27
e_1_2_7_8_2
e_1_2_7_7_2
e_1_2_7_6_2
e_1_2_7_19_2
e_1_2_7_18_2
e_1_2_7_17_2
e_1_2_7_16_2
e_1_2_7_15_2
e_1_2_7_14_2
e_1_2_7_13_2
e_1_2_7_12_2
e_1_2_7_11_2
e_1_2_7_27_2
Ward MM (e_1_2_7_9_2) 2000; 27
e_1_2_7_25_2
e_1_2_7_23_2
e_1_2_7_22_2
e_1_2_7_21_2
e_1_2_7_20_2
References_xml – volume: 17
  start-page: 6
  year: 2008
  end-page: 10
  article-title: Vitamin D, immunity and lupus
  publication-title: Lupus
– volume: 54
  start-page: S431
  issue: Suppl
  year: 2006
  article-title: The threshold of vitamin D required for optimal immune regulation: implications for patients with lupus
  publication-title: Arthritis Rheum
– volume: 1109
  start-page: 385
  year: 2007
  end-page: 400
  article-title: Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases
  publication-title: Ann N Y Acad Sci
– volume: 28
  start-page: 2535
  year: 2001
  end-page: 9
  article-title: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia
  publication-title: J Rheumatol
– volume: 48
  start-page: 210
  year: 2009
  end-page: 2
  article-title: Vitamin D and autoimmune rheumatic diseases
  publication-title: Rheumatology (Oxford)
– volume: 61
  start-page: 1387
  year: 2009
  end-page: 95
  article-title: 25‐hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 10
  start-page: 273
  year: 2008
  end-page: 80
  article-title: The link between vitamin D deficiency and systemic lupus erythematosus
  publication-title: Curr Rheumatol Rep
– volume: 326
  start-page: 124
  year: 2003
  article-title: Iron supplementation for unexplained fatigue in non‐anaemic women: double blind randomised placebo controlled trial
  publication-title: BMJ
– volume: 40
  start-page: 1725
  year: 1997
  article-title: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
  publication-title: Arthritis Rheum
– volume: 20
  start-page: 532
  year: 2008
  end-page: 7
  article-title: Vitamin D in systemic lupus erythematosus
  publication-title: Curr Opin Rheumatol
– volume: 1109
  start-page: 550
  year: 2007
  end-page: 7
  article-title: Anti‐vitamin D, vitamin D in SLE: preliminary results
  publication-title: Ann N Y Acad Sci
– volume: 5
  start-page: 114
  year: 2006
  end-page: 7
  article-title: Vitamin D deficiency in systemic lupus erythematosus
  publication-title: Autoimmun Rev
– volume: 57
  start-page: 1348
  year: 2007
  end-page: 57
  article-title: Measurement of fatigue in systemic lupus erythematosus: a systematic review
  publication-title: Arthritis Rheum
– volume: 1069
  start-page: 322
  year: 2006
  end-page: 45
  article-title: Predicting and preventing autoimmunity, myth or reality?
  publication-title: Ann N Y Acad Sci
– volume: 75
  start-page: 611
  year: 2002
  end-page: 5
  article-title: Vitamin D deficiency, muscle function, and falls in elderly people
  publication-title: Am J Clin Nutr
– volume: 47
  start-page: 920
  year: 2008
  end-page: 3
  article-title: Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
  publication-title: Rheumatology (Oxford)
– volume: 50
  start-page: 2195
  year: 2004
  end-page: 7
  article-title: How accurate are assays for 25‐hydroxyvitamin D? Data from the International Vitamin D External Quality Assessment Scheme
  publication-title: Clin Chem
– volume: 80
  start-page: S1717
  issue: Suppl
  year: 2004
  end-page: 20
  article-title: Vitamin D status, 1,25‐dihydroxyvitamin D3, and the immune system
  publication-title: Am J Clin Nutr
– volume: 27
  start-page: 373
  year: 2000
  end-page: 6
  article-title: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison
  publication-title: J Rheumatol
– volume: 168
  start-page: 1629
  year: 2008
  end-page: 37
  article-title: 25‐hydroxyvitamin D levels and the risk of mortality in the general population
  publication-title: Arch Intern Med
– volume: 27
  start-page: 664
  year: 2000
  end-page: 70
  article-title: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus
  publication-title: J Rheumatol
– volume: 357
  start-page: 266
  year: 2007
  end-page: 81
  article-title: Vitamin D deficiency
  publication-title: N Engl J Med
– volume: 179
  start-page: 1634
  year: 2007
  end-page: 47
  article-title: Modulatory effects of 1,25‐dihydroxyvitamin D on human B cell differentiation
  publication-title: J Immunol
– volume: 205
  start-page: 255
  year: 2009
  end-page: 60
  article-title: 25‐Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey
  publication-title: Atheroclerosis
– volume: 14
  start-page: 397
  year: 1995
  end-page: 400
  article-title: Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25‐hydroxyvitamin D3 in patients with systemic lupus erythematosus
  publication-title: Clin Rheumatol
– volume: 335
  start-page: 99
  year: 2008
  end-page: 104
  article-title: Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus
  publication-title: Am J Med Sci
– volume: 27
  start-page: 373
  year: 2000
  ident: e_1_2_7_10_2
  article-title: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison
  publication-title: J Rheumatol
– ident: e_1_2_7_2_2
  doi: 10.1097/BOR.0b013e32830a991b
– ident: e_1_2_7_4_2
  doi: 10.1056/NEJMra070553
– ident: e_1_2_7_6_2
  doi: 10.1007/s11926-008-0044-3
– ident: e_1_2_7_12_2
  doi: 10.1373/clinchem.2004.040683
– ident: e_1_2_7_14_2
  doi: 10.1016/j.autrev.2005.05.009
– ident: e_1_2_7_7_2
  doi: 10.1093/rheumatology/ken121
– ident: e_1_2_7_25_2
  doi: 10.1002/art.24785
– ident: e_1_2_7_16_2
  doi: 10.1196/annals.1398.061
– ident: e_1_2_7_15_2
  doi: 10.4049/jimmunol.179.3.1634
– ident: e_1_2_7_23_2
  doi: 10.1177/0961203307085879
– ident: e_1_2_7_5_2
  doi: 10.1093/rheumatology/ken394
– ident: e_1_2_7_22_2
  doi: 10.1196/annals.1351.031
– ident: e_1_2_7_18_2
  doi: 10.1097/MAJ.0b013e318134eeb6
– volume: 27
  start-page: 664
  year: 2000
  ident: e_1_2_7_9_2
  article-title: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus
  publication-title: J Rheumatol
– volume: 54
  start-page: S431
  year: 2006
  ident: e_1_2_7_24_2
  article-title: The threshold of vitamin D required for optimal immune regulation: implications for patients with lupus
  publication-title: Arthritis Rheum
– volume: 28
  start-page: 2535
  year: 2001
  ident: e_1_2_7_26_2
  article-title: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia
  publication-title: J Rheumatol
– ident: e_1_2_7_19_2
  doi: 10.1093/ajcn/75.4.611
– ident: e_1_2_7_17_2
  doi: 10.1196/annals.1398.044
– ident: e_1_2_7_21_2
  doi: 10.1093/ajcn/80.6.1717S
– ident: e_1_2_7_20_2
  doi: 10.1016/j.atherosclerosis.2008.10.033
– ident: e_1_2_7_3_2
  doi: 10.1001/archinte.168.15.1629
– ident: e_1_2_7_8_2
  doi: 10.1002/art.1780400928
– ident: e_1_2_7_27_2
  doi: 10.1002/art.23113
– ident: e_1_2_7_11_2
  doi: 10.1136/bmj.326.7399.1124
– ident: e_1_2_7_13_2
  doi: 10.1007/BF02207671
SSID ssj0000328839
Score 2.3441415
Snippet Objective To analyze whether changes in serum 25‐hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus...
To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1160
SubjectTerms Adult
Cholecalciferol
Cross-Sectional Studies
Fatigue
Female
Humans
Lupus Erythematosus, Systemic - blood
Male
Middle Aged
Treatment Outcome
Vitamin D - analogs & derivatives
Title Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Facr.20186
https://www.ncbi.nlm.nih.gov/pubmed/20235208
https://www.proquest.com/docview/748940893
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3LS91AFIcHcSFu-rKP24ccpIsujE5mJpPErkQrItiFVLiLQphnuXjNFXNTaP3nnZNJIvYB4iohzAzJPH-ZOec7hHykQSQL9MbJhKeJ0KlNSmNZYrXIWO64khb9nU-_yuNzcTLNpivk8-ALE_kQ44YbjoxuvsYBrnSzewcNVQZxnmmBuO2US-TmH56xcX8FOXFFF0gMF7VESDEdwEKU7Y6Z7y9Hf2nM-5K1W3OOnpLvw9tGU5OLnXapd8zvP0COj_ycZ-RJr0VhP3ae52TF1S_I2ml_2r5BbqLrQQOzGn7OluoyXA9hjmZG3bOeydoAbuZCZELPDMzbq7YBd_0rAmEXTdvsQaQkN7CowYdsP1q3Df3hEKBvBYaw2AZVW7DqMsxxL8n50ZdvB8dJH6whMUGTySQXkmutfe4o-g9RadPcS-uo4qXztshLw6UW2igpvTaOea_SIshLz22ZCctfkdV6Ubs3BIwNslBLxMTwMI8zxfNSUcfCv02Waqcn5NPQZpXpSeYYUGNeRQYzq0JlVl1lTsjWmPQq4jv-lQiGhq_C4MITE1W7RdtUiOYRNEi6CXkdO8RYCoadzxgtwst0zfr_4qv9g7Pu5u3Dk74j69FMAS0N35PV5XXrPgT1s9SbXTe_BSmGAKk
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFH4qRQIu7MuwWogDh6Z1HMdJEJeqUA3Q6aFqpbmgyCsaMc1UzQQJ-PP42UlQWSTEKVH0bDleP7_lewAvqAfJHKNxcu5owlVqkkoblhjFc1bYTAqD8c6zQzE94e_n-XwDXg-xMJEfYlS44coI-zUucFRI7_xkDZUa-TzTUlyCy8E-h5DoiI0aFmSKK0MqMTzWEi8yH6iFKNsZS188kH5DmRdBazh19m_Ax6G90dnk83a3Vtv62y9Ujv_7Qzfheg9HyW6cP7dgwza34cqsN7jfge8x-qAli4Z8WazlqX--IUv0NArfelrWlqA-l0Ra6IUmy-6sa4k9_xo5YVdt174ikSi5JauGOF_sU2e3SG8fIhhegVkstohsDDHy1G9zd-Fk_-3x3jTp8zUk2sMykRRcZEopV1iKIURUmLRwwlgqs8o6UxaVzoTiSkshnNKWOSfT0iNMl5kq5ya7B5vNqrEPgGjjkaESyBST-a2cyayoJLXMX2_yVFk1gZfDoNW6JzPHnBrLOtIws9p3Zh06cwLPR9GzyODxJyEyjHzt1xcaTWRjV11bIzsPpx7VTeB-nBFjLZh5Pme09I0J4_r36uvdvaPw8vDfRZ_B1enx7KA-eHf44RFci14L6Hj4GDbX55194sHQWj0Nc_4HLjwExw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3ba9RAFIcPtYXii1qv63UQH3xo2slkMkn0qbRdamuLFAv7IIS5yuI2uzQbwfafd04miVQtiE8JYWZI5vrLzDnfAXhDvUjm6I2TckcjrmITFdqwyCiesswmUhj0dz4-EQdn_HCSTlbgfe8LE_gQw4Ybjox2vsYBvjBu-xc0VGrEeca5uAVrXPhlEhXRKRs2WBAUl7eRxHBVi7jgk54sRNn2kPv6evSHyLyuWdtFZ3wXvvSvG2xNvm01S7WlL38jOf7n99yDO50YJTuh92zAiq3uw_pxd9z-AK6C70FNphX5Pl3Kc3_dIzO0M2qfdVDWmuBuLglQ6Kkms2bR1MRe_AhE2Hnd1O9IwCTXZF4R57N9bewm6U6HCDpXYAyLTSIrQ4w895PcQzgb73_ePYi6aA2R9qJMRBkXiVLKZZaiAxEVJs6cMJbKpLDO5FmhE6G40lIIp7Rlzsk49_rSJaZIuUkewWo1r-wTINp4XagEcmISP5EzmWSFpJb5n5s0VlaN4G3fZqXuUOYYUWNWBggzK31llm1ljuD1kHQR-B1_S0T6hi_96MIjE1nZeVOXyObh1Gu6ETwOHWIoBePOp4zm_mXaZr25-HJn97S9efrvSV_B-qe9cfnxw8nRM7gdTBbQ6vA5rC4vGvvCK6Gletn2-J8kLAN2
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+vitamin+D+levels+in+patients+with+systemic+lupus+erythematosus%3A+Effects+on+fatigue%2C+disease+activity%2C+and+damage&rft.jtitle=Arthritis+care+%26+research+%282010%29&rft.au=Ruiz%E2%80%90Irastorza%2C+Guillermo&rft.au=Gordo%2C+Susana&rft.au=Olivares%2C+Nerea&rft.au=Egurbide%2C+Maria%E2%80%90Victoria&rft.date=2010-08-01&rft.issn=2151-464X&rft.eissn=2151-4658&rft.volume=62&rft.issue=8&rft.spage=1160&rft.epage=1165&rft_id=info:doi/10.1002%2Facr.20186&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_acr_20186
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2151-464X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2151-464X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2151-464X&client=summon